VolitionRx Limited (VNRX) Signs LOI to Develop NETosis Lateral Flow Test
VolitionRx (VNRX) signed a non-binding LOI with Missionpharma to develop, manufacture, and distribute a lateral flow test for NETosis, targeting decentralized use. The test aims at applications in low- and middle-income countries and neonatal sepsis triage.
How this was made

The 30-second read
Why it matters
The LOI signals early partnership but lacks binding commitments, limiting immediate market impact.
Market read
Early-stage partnership with modest immediate relevance; may affect niche biotech investors.
What to watch
absence of binding terms, regulatory approvals, and purchase commitments
Background
VolitionRx is a biotech company developing a NETosis lateral flow test for sepsis triage.
Market effects
potential interest in NETosis diagnostics within biotech sector
limited to Australian biotech market
minimal
Counterpoint
LOI may not lead to commercial product; risk of delay or termination
Key entities
- companyVolitionRx Limited
Biotech firm developing NETosis test
- companyMissionpharma
Partner for development and distribution
